ArticleFrontiers in oncology2023

A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China.

Jinghong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.